Targeting low-density lipoprotein receptors with protein-only nanoparticles
Source abstract
Abstract
Low-density lipoprotein receptors (LDLR) are appealing cell surface targets in drug delivery, as they are expressed in the blood–brain barrier (BBB) endothelium and are able to mediate transcytosis of functionalized drugs for molecular therapies of the central nervous system (CNS). On the other hand, brain-targeted drug delivery is currently limited, among others, by the poor availability of biocompatible vehicles, as most of the nanoparticles under development as drug carriers pose severe toxicity issues. In this context, protein nanoparticles offer functional versatility, easy and cost-effective bioproduction, and full biocompatibility. In this study, we have designed and characterized several chimerical proteins containing different LDLR ligands, regarding their ability to bind and internalize target cells and to self-organize as viral mimetic nanoparticles of about 18 nm in diameter. While the self-assembling of LDLR-binding proteins as nanoparticles positively influences cell penetration in vitro, the nanoparticulate architecture might be not favoring BBB crossing in vivo. These findings are discussed in the context of the use of nanostructured materials as vehicles for the systemic treatment of CNS diseases. © 2015, Springer Science+Business Media Dordrecht.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Aris A, Villaverde A (2004) Modular protein engineering for non-viral gene therapy. Trends Biotechnol 22:371–37710.1016/j.tibtech.2004.05.004 ↗
2. Barbu E, Molnar E, Tsibouklis J, Gorecki DC (2009) The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier. Expert Opin Drug Deliv 6:553–56510.1517/17425240902939143 ↗
3. Cespedes MV, Unzueta U, Tatkiewicz W, Sanchez-Chardi A, Conchillo-Sole O, Alamo P et al (2014) In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano 8(5):4166–417610.1021/nn4055732 ↗
4. Chen GQ (2012) New challenges and opportunities for industrial biotechnology. Microb Cell Fact 11:11110.1186/1475-2859-11-111 ↗
5. Corchero JL, Gasser B, Resina D, Smith W, Parrilli E, Vazquez F et al (2013) Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv 31:140–15310.1016/j.biotechadv.2012.09.001 ↗
6. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Beth M et al (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118:4002–401310.1172/JCI36663 ↗
7. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–107210.1124/jpet.107.131318 ↗
8. Ferrer-Miralles N, Villaverde A (2013) Bacterial cell factories for recombinant protein production; expanding the catalogue. Microb Cell Fact 12:11310.1186/1475-2859-12-113 ↗
9. Ferrer-Miralles N, Rodriguez-Carmona E, Corchero JL, Garcia-Fruitos E, Vazquez E, Villaverde A (2013) Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Crit Rev Biotechnol. doi: 10.3109/07388551.2013.833163
10. Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillen ZP, Prieto J et al (2012) The fusion protein of IFN-alpha and apolipoprotein A-I crosses the blood–brain barrier by a saturable transport mechanism. J Immunol 188:3988–399210.4049/jimmunol.1101598 ↗
11. Hellinger E, Veszelka S, Tóth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Háda V, Nakagawa S, Duy TD, Niwa M, Deli MA, Vastag M (2012) Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood–brain barrier penetration models. Eur J Pharm Biopharm 82:340–35110.1016/j.ejpb.2012.07.020 ↗
12. Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–110610.1016/j.drudis.2008.09.005 ↗
13. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaele D et al (2007) Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8:793–79910.1021/bm060711a ↗
14. Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R et al (2007) Apolipoprotein A-I coating of protamine–oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood–brain barrier. J Control Release 117:301–31110.1016/j.jconrel.2006.11.020 ↗
15. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C et al (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J Drug Target 10:317–32510.1080/10611860290031877 ↗
16. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A et al (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11:308–31610.1158/1535-7163.MCT-11-0566 ↗
17. Lockman PR, Mumper RJ, Khan MA, Allen DD (2002) Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm 28:1–1310.1081/DDC-120001481 ↗
18. Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y (2014) Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int 2014. doi: 10.1155/2014/18054910.1155/2014/180549 ↗
19. Maggie JM (2011) Peptide for transmigration across blood brain barrier and delivery systems comprising the same. United States Patent Application Publication US 2011/0165079 A1
20. Mahalik S, Sharma AK, Mukherjee KJ (2014) Genome engineering for improved recombinant protein expression in Escherichia coli. Microb Cell Fact 13:17710.1186/s12934-014-0177-1 ↗
21. Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG (2000) Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J Lipid Res 41:205–21310.1016/S0022-2275(20)32054-X ↗
22. Nehate C, Jain S, Saneja A, Khare V, Alam N, Dubey R et al (2014) Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv 1(6):666–68610.2174/1567201811666140609154949 ↗
23. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM (2007) Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 124:163–17110.1016/j.jconrel.2007.09.007 ↗
24. Pardridge WM (2010) Biopharmaceutical drug targeting to the brain. J Drug Target 18(3):157–16710.3109/10611860903548354 ↗
25. Peluffo H, Unzueta U, Negro-Demontel ML, Xu Z, Váquez E, Ferrer-Miralles N, Villaverde A (2015) BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol Adv 33:277–28710.1016/j.biotechadv.2015.02.004 ↗
26. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M et al (2011) Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 156:341–34610.1016/j.jbiotec.2011.06.037 ↗
27. Rodriguez-Carmona E, Villaverde A (2010) Nanostructured bacterial materials for innovative medicines. Trends Microbiol 18:423–43010.1016/j.tim.2010.06.007 ↗
28. Schneider WJ, Beisiegel U, Goldstein JL, Brown MS (1982) Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem 257:2664–267310.1016/S0021-9258(18)34975-5 ↗
29. Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood–brain barrier. Proc Natl Acad Sci USA 104:7594–759910.1073/pnas.0702170104 ↗
30. Su T, Stanley KK (1998) Opposite sorting and transcytosis of the polymeric immunoglobulin receptor in transfected endothelial and epithelial cells. J Cell Sci 111(Pt 9):1197–120610.1242/jcs.111.9.1197 ↗
31. Unzueta U, Ferrer-Miralles N, Cedano J, Zikung X, Pesarrodona M, Saccardo P et al (2012a) Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials 33:8714–872210.1016/j.biomaterials.2012.08.033 ↗
32. Unzueta U, Cespedes MV, Ferrer-Miralles N, Casanova I, Cedano JA, Corchero JL et al (2012b) Intracellular CXCR4 + cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomed 7:4533–4544
33. Unzueta U, Saccardo P, Domingo-Espin J, Cedano J, Conchillo-Sole O, Garcia-Fruitos E et al (2014) Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. Nanomedicine 10:535–54110.1016/j.nano.2013.11.006 ↗
34. Van DS, Bronselaer A, Nielandt J, Stalmans S, Wynendaele E, Audenaert K et al (2012) Brainpeps: the blood–brain barrier peptide database. Brain Struct Funct 217:687–71810.1007/s00429-011-0375-0 ↗
35. Vazquez E, Villaverde A (2013) Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine (Lond) 8:1895–189810.2217/nnm.13.164 ↗
36. Vazquez E, Ferrer-Miralles N, Villaverde A (2008) Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today 13:1067–107410.1016/j.drudis.2008.08.008 ↗
37. Vazquez E, Roldan M, Diez-Gil C, Unzueta U, Domingo-Espin J, Cedano J et al (2010) Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) 5:259–26810.2217/nnm.09.98 ↗
38. Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T et al (2012) Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood–brain barrier model. PLoS One 7(3):e3256810.1371/journal.pone.0032568 ↗